Last reviewed 2026-04-23 · How we verify

CDP6038

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate (PHASE1, PHASE2)
• Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy (PHASE2)
• The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis (PHASE2)
• Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056 (PHASE2)
• Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy (PHASE2)
• A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease (PHASE2)
• The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males (PHASE1)
• Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.